SAN

76.64

-0.42%↓

ARGX

701.8

+0.69%↑

SHL.DE

35.24

+1.94%↑

FRE

37.79

-0.84%↓

PHIA

23.21

-1.07%↓

SAN

76.64

-0.42%↓

ARGX

701.8

+0.69%↑

SHL.DE

35.24

+1.94%↑

FRE

37.79

-0.84%↓

PHIA

23.21

-1.07%↓

SAN

76.64

-0.42%↓

ARGX

701.8

+0.69%↑

SHL.DE

35.24

+1.94%↑

FRE

37.79

-0.84%↓

PHIA

23.21

-1.07%↓

SAN

76.64

-0.42%↓

ARGX

701.8

+0.69%↑

SHL.DE

35.24

+1.94%↑

FRE

37.79

-0.84%↓

PHIA

23.21

-1.07%↓

SAN

76.64

-0.42%↓

ARGX

701.8

+0.69%↑

SHL.DE

35.24

+1.94%↑

FRE

37.79

-0.84%↓

PHIA

23.21

-1.07%↓

Kodu・Aktsiate loetelu・Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi SA

Avatud

SektorTervishoid

60.95 0.66

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

60.15

Max

60.95

Põhinäitajad
By Trading Economics
Sissetulek	-33M 9.5M
Müük	-66M 152M
P/E Sektori keskmine	25.593 50.102
Aktsiakasum	0.185
Kasumimarginaal	6.216
Töötajad	1,950
EBITDA	-45M 18M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+22.46% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	23. juuli 2026

Turustatistika
By TradingEconomics
Turukapital	-972M 3.1B
Eelmine avamishind	60.29
Eelmine sulgemishind	60.95

Uudiste sentiment

By Acuity

50%

154 / 344 Pingereas Healthcare

Laboratorios Farmaceuticos Rovi SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

26. mai 2026, 16:52 UTC

Uudisväärsed sündmused

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

26. mai 2026, 23:57 UTC

Tulu

Sociedad Quimica 1Q Rev $1.76B >SQM

26. mai 2026, 23:57 UTC

Tulu

Sociedad Quimica 1Q EPS $1.28 >SQM

26. mai 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

26. mai 2026, 21:54 UTC

Tulu

Webco Industries 3Q EPS $11.61 >WEBC

26. mai 2026, 21:54 UTC

Tulu

Webco Industries 3Q Sales $179.6M >WEBC

26. mai 2026, 21:48 UTC

Market Talk

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

26. mai 2026, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

26. mai 2026, 20:58 UTC

Omandamised, ülevõtmised, äriostud

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

26. mai 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26. mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

26. mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

26. mai 2026, 19:22 UTC

Market Talk

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

26. mai 2026, 19:17 UTC

Market Talk

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

26. mai 2026, 18:56 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

26. mai 2026, 18:03 UTC

Market Talk

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

26. mai 2026, 17:42 UTC

Market Talk

Grains Await Fresh Trading Catalyst -- Market Talk

26. mai 2026, 17:33 UTC

Market Talk

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

26. mai 2026, 17:21 UTC

Market Talk

Canada Faces a Labor Market Squeeze -- Market Talk

26. mai 2026, 16:52 UTC

Market Talk

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

26. mai 2026, 16:43 UTC

Market Talk

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

26. mai 2026, 16:24 UTC

Market Talk

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

26. mai 2026, 16:21 UTC

Market Talk

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

26. mai 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26. mai 2026, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

26. mai 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

26. mai 2026, 16:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Auto & Transport Roundup: Market Talk

26. mai 2026, 16:16 UTC

Market Talk

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

26. mai 2026, 16:01 UTC

Market Talk

Bitcoin Lower as Stress Builds for Holders -- Market Talk

26. mai 2026, 15:21 UTC

Market Talk

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Laboratorios Farmaceuticos Rovi SA Prognoos

Hinnasiht

By TipRanks

22.46% tõus

12 kuu keskmine prognoos

Keskmine 73.6 EUR 22.46%

Kõrge 83 EUR

Madal 64.2 EUR

Põhineb 2 Wall Streeti analüütiku instrumendi Laboratorios Farmaceuticos Rovi SA 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi Laboratorios Farmaceuticos Rovi SA aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

154 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.